Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia - 10/10/20
Doi : 10.1016/j.jaad.2020.05.129
Abhijeet Kumar Jha, MD a, Sidharth Sonthalia, MD, DNB, MNAMS b, MD Zeeshan, MD a, Keshavamurthy Vinay, MD, DNB, MNAMS c, ⁎ 
a Department of Skin and Venereal Diseases, Patna Medical College, Bihar, India
b Department of Dermatology and Dermoscopy, Skinnocence: the Skin Clinic and Research Centre, Gurugram, India
c Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
∗Correspondence to: Keshavamurthy Vinay, MD, DNB, MNAMS, Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, IndiaDepartment of Dermatology, Venereology and LeprologyPostgraduate Institute of Medical Education and ResearchSector 12Chandigarh160012India
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1491-1493 - novembre 2020 Retour au numéro
Article précédent
- Apremilast for the off-label treatment of lichenoid and interface dermatoses
- Surya Ravichandran, Meenal K. Kheterpal
- Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review
- Nirav Shah, Leah Cohen, Lucia Seminario-Vidal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?